Table 2.
Outcomes of RFA for ESCN.
| First author | Year | Mean or median (IQR) number of RFA | CR rate | Defined CR duration (m) | Recurrence (%) | Complications | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Stricture rate | Mean or median (IQR) number of dilation | Perforation | Bleeding/hematoma | Laceration | ||||||
| Pouw [44] | 2008 | 1 | 100% | 4 | 0 | 0 | — | 0 | 0 | 0 |
| Becker [38] | 2011 | 1.7 | 100% | 10† | 0 | 0 | — | 0 | 0 | 0 |
| Vilsteren [34] | 2011 | 2 (1-3) | 100% | 2 months after last treatment | 0 | 23% | 3 (1-12) | 1 | 1 | 2 |
| Bergman [35] | 2011 | 1.7 | 97% | 12 | 1 (3%) | 14% | 2.5 (2-4) | 0 | 0 | 1 |
| Haidry [41] | 2013 | 1 (1-3) | 50% | 12 | 10 (50%) | 20% | 2.5 | 0 | 2 | 1 |
| Wang [45] | 2014 | 1 (1-2) | 85.7% | 6 | 1 (14.3%)‡ | 28.6% | 5 (NR) | 0 | 1 | 0 |
| Wang [8] | 2015 | NR | 94.4% | 12 | 1 (5.6%) | 22.2% | 5.5 (NR) | 0 | 0 | 0 |
| He [39] | 2015 | 1.9 | 84% | 12 | 15 (16%) | 21% | 4 (2-6) | 0 | 1 | 4 |
| Wang [46] | 2016 | NR | 93% | 12 | NR | 17% | 5 | 0 | 1 | 1 |
| Wang [43] | 2017 | NR | 100% | 12 | 0 | 0 | — | 0 | 2 | 1 |
| Wang [26] | 2018 | 1 (1-2) | 86% | 12 | 6 (20%) | 14% | 3 (2-8) | 0 | 2 | 1 |
| Yu [40] | 2019 | 1.9 | 86% | 60 | 11 (14%) | 21% | NR | 0 | 0 | 0 |
RFA: radiofrequency ablation; ESCN: esophageal squamous cell neoplasia; IQR: interquartile range; CR: complete remission; NR: not reported. †No specific CR duration was defined. All patients had achieved CR during a follow-up of 10-28 month. ‡This patient was not eligible for further treatment for other severe clinical conditions.